despit
extens
global
eff
ort
fi
ght
killer
infecti
diseas
still
caus
one
four
death
worldwid
import
caus
longterm
function
disabl
aris
tissu
damag
continu
epidem
tuberculosi
hiv
malaria
infl
uenza
emerg
novel
zoonot
pathogen
repres
major
clinic
manag
challeng
worldwid
newer
approach
improv
treatment
outcom
need
reduc
high
morbid
mortal
caus
infecti
diseas
recent
insight
pathogenhost
interact
pathogenesi
infl
ammatori
pathway
host
innat
acquir
immun
respons
lead
identifi
cation
develop
wide
rang
hostdirect
therapi
diff
erent
mechan
action
hostdirect
therapeut
strategi
becom
viabl
adjunct
standard
antimicrobi
treatment
hostdirect
therapi
includ
commonli
use
drug
noncommunic
diseas
good
safeti
profi
le
immunomodulatori
agent
biolog
eg
monoclon
antibodi
nutrit
product
cellular
therapi
use
patient
immun
bone
marrow
mesenchym
stromal
cell
discuss
clinic
relev
exampl
progress
identifi
hostdirect
therapi
adjunct
treatment
option
bacteri
viral
parasit
infecti
diseas
lancet
infect
di
list
consortium
partner
avail
http
wwwunzauclmsorghdtnetpartn
infecti
diseas
lead
caus
morbid
mortal
worldwid
highincom
countri
mortal
respiratori
tract
infect
remain
high
despit
access
qualiti
health
servic
avail
antibiot
therapi
intermitt
emerg
new
zoonot
pathogen
increas
incid
treatmentresist
infect
draw
attent
limit
current
antimicrobi
treatment
portfolio
urgent
need
altern
manag
strategi
evolutionari
term
hostpathogen
interact
depend
microb
surviv
without
caus
harm
host
host
innat
adapt
immun
surveil
mechan
govern
whether
infect
contain
progress
clinic
diseas
either
recoveri
death
sever
host
factor
aff
ect
antimicrobi
treatment
outcom
respons
progress
diseas
infect
poor
treatment
respons
tissu
damag
longterm
function
disabl
increas
mortal
factor
includ
immun
dysregul
caus
aberr
excess
host
infl
ammatori
respons
infect
stress
immunosuppress
drug
poor
live
condit
socioeconom
factor
micronutri
defi
cienci
hiv
malnutrit
alcohol
substanc
misus
comorbid
noncommunic
diseas
diabet
cancer
smoke
chronic
obstruct
pulmonari
diseas
past
year
renaiss
scientifi
c
research
strategi
target
host
factor
rather
pathogen
compon
directli
open
novel
treatment
approach
term
hostdirect
therapi
hostdirect
therapi
product
augment
host
defenc
mechan
modul
excess
infl
ammat
lead
improv
clinic
treatment
outcom
shown
reduc
morbid
mortal
endorgan
damag
longterm
function
recoveri
rang
hostdirect
therapi
identifi
ed
diff
erent
mechan
action
fi
gure
regard
viabl
adjunct
standard
antimicrobi
treatment
hostdirect
therapi
improv
host
cellular
respons
pathogen
target
diseasecaus
virul
factor
fi
gure
activ
innat
adapt
immun
respons
immunolog
memori
fi
gure
despit
avail
antimicrobi
drug
infecti
diseas
lead
caus
morbid
mortal
worldwid
widespread
emerg
antimicrobi
resist
call
novel
intervent
addit
new
antimicrobi
develop
rang
host
factor
respons
develop
diseas
poor
treatment
respons
increas
mortal
includ
immun
dysregul
caus
comorbid
noncommunic
diseas
diabet
cancer
smoke
chronic
obstruct
pulmonari
diseas
past
year
renaiss
scientifi
c
research
strategi
target
host
factorsrath
pathogen
compon
directlyi
lead
develop
wide
rang
hostdirect
therapi
target
modifi
biolog
pathway
achiev
posit
clinic
treatment
outcom
hostdirect
therapi
augment
host
cellular
respons
pathogen
target
diseasecaus
virul
factor
activ
innat
adapt
protect
immun
respons
modul
excess
infl
ammat
lead
reduc
morbid
mortal
endorgan
damag
hostdirect
therapi
includ
commonli
use
safe
cheap
drug
noncommunic
diseas
biolog
nutrit
product
cellular
therapi
use
patient
immun
mesenchym
stromal
cell
broad
spectrum
effi
caci
hostdirect
therapi
could
also
use
treatment
infecti
diseas
epidem
potenti
associ
high
mortal
hostdirect
therapi
addit
uniqu
benefi
prevent
reduc
develop
antibiot
resist
exampl
hostdirect
therapi
includ
commonli
use
aff
ordabl
drug
noncommunic
diseas
good
safeti
profi
le
immunomodulatori
agent
biolog
nutrit
product
cellular
therapi
use
patient
immun
mesenchym
stromal
cell
tabl
see
appendix
discuss
potenti
host
factor
target
hostdirect
therapi
infecti
diseas
studi
hostdirect
therapi
also
enabl
new
insight
underli
mechan
pathogenesi
infl
ammatori
pathway
host
innat
acquir
immun
respons
review
discuss
clinic
relev
exampl
progress
identifi
cation
candid
hostdirect
therapi
adjunct
treatment
option
bacteri
viral
parasit
infecti
diseas
tuberculosi
common
caus
death
infecti
diseas
worldwid
sinc
declar
tuberculosi
global
emerg
major
focu
develop
new
drug
target
mycobacterium
tuberculosi
caus
pathogen
decad
notion
tuberculosi
sole
caus
continu
worldwid
tuberculosi
pandem
led
focu
treatment
patient
tuberculosi
whorecommend
combin
antituberculosi
antibiot
therapi
focu
still
thrive
although
billion
peopl
world
latent
tuberculosi
infect
develop
activ
diseas
furthermor
substanti
declin
tuberculosi
europ
north
america
fi
rst
half
centuri
occur
well
antibiot
era
estim
million
peopl
die
tuberculosi
estim
case
multidrugresist
mdr
extens
drugresist
xdr
tuberculosi
suggest
host
factor
import
role
achiev
antim
tuberculosi
immun
respons
tuberculosi
larg
intracellular
natur
intact
tcell
respons
cytotox
lymphocyt
cytotox
lymphocyt
natur
killer
cell
product
need
restrict
tuberculosi
growth
pulmonari
tissu
patholog
substanti
tissu
destruct
subdu
protect
antim
tuberculosi
immun
respons
note
patient
tuberculosi
predominantli
aff
ect
tumour
necrosi
factor
tnf
infl
ammat
improv
treatment
drugsensit
mdr
tuberculosi
high
prioriti
new
antim
tuberculosi
drug
clinic
assess
substanti
safeti
concern
furthermor
resist
hostdirect
therapi
focu
amelior
sever
diseas
improv
treatment
outcom
hostdirect
therapi
constitut
rang
therapeut
agent
repurpos
drug
small
molecul
synthet
nucleic
acid
biolog
monoclon
antibodi
cytokin
cellular
therapi
recombin
protein
micronutri
wwwthelancetcominfect
vol
april
review
like
develop
new
tuberculosi
drug
greatest
clinic
need
tuberculosi
treatment
intervent
could
reduc
lengthi
durat
tuberculosi
therapi
current
month
patient
drugsensit
tuberculosi
month
patient
mdr
xdr
tuberculosi
thu
improv
patient
complianc
reduc
longterm
toxic
invigor
immun
respons
erad
contain
tuberculosi
dampen
excess
infl
ammat
repair
tissu
damag
prevent
longterm
pulmonari
damag
function
disabl
reduc
high
mortal
mdr
xdr
tuberculosi
expand
portfolio
hostdirect
therapi
use
adjunct
treatment
tuberculosi
therapi
improv
treatment
outcom
shorten
durat
therapi
reduc
lung
patholog
longterm
function
disabl
drugsensit
drugresist
tuberculosi
tabl
hostdirect
therapi
may
decreas
local
infl
ammatori
tissu
patholog
includ
caus
tuberculosisassoci
immun
reconstitut
infl
matori
syndrom
exampl
hostdirect
therapi
current
develop
cellular
therapi
use
patient
bone
marrowderiv
mesenchym
stromal
cell
repurpos
commonli
use
drug
diabet
epilepsi
peptic
ulcer
hypercholesterolaemia
asthma
cancer
arthriti
micronutri
immunemodul
antimicrobi
peptid
induc
checkpoint
inhibitor
specifi
c
immunebas
therapi
therapeut
vaccin
multin
consortia
establish
take
therapi
forward
control
clinic
trial
streptococcu
pneumonia
gramposit
bacterium
remain
major
caus
childhood
adult
morbid
mortal
worldwid
despit
avail
eff
ectiv
antibiot
therapi
larg
associ
communityacquir
pneumonia
often
caus
invas
pneumococc
diseas
aff
ect
organ
bodi
cellmedi
humor
immun
respons
oper
prevent
diseas
human
be
pathogenesi
pneumonia
associ
overt
infl
ammatori
respons
eventu
caus
lung
damag
death
thu
sever
adjunct
hostdirect
intervent
investig
use
corticosteroid
pneumonia
remain
controversi
data
support
use
cortico
steroid
case
communityacquir
pneumonia
limit
prospect
randomis
clinic
studi
patient
communityacquir
pneumonia
prednisolon
led
overal
improv
surviv
treatment
concomit
slightli
shorter
hospit
stay
reduc
need
mechan
ventil
compar
placebo
corticosteroid
also
prevent
hear
loss
neurolog
sequela
bacteri
mening
although
clinic
use
macrolid
antibiot
specifi
calli
target
caus
bacteria
macrolid
might
addit
hostdirect
eff
ect
treat
communityacquir
pneumonia
preclin
assess
azithromycin
mice
secondari
pneumonia
infect
follow
primari
exposur
infl
uenza
viru
potenti
antiinfl
ammatori
eff
ect
mark
reduct
neutrophil
infl
ux
promot
dampen
immunopatholog
outcom
lung
retrospect
prospect
studi
shown
macrolidecontain
antibiot
regimen
decreas
mortal
patient
communityacquir
pneu
monia
although
studi
shown
signifi
cant
benefi
regimen
addit
macrolid
fl
uoroquinolon
seem
provid
improv
figur
hostdirect
therapi
mean
counteract
antimicrobi
resist
pathogen
develop
resist
antimicrobi
therapi
via
variou
factor
includ
modifi
cation
cellsurfac
protein
intracellular
enzym
bacteria
parasit
modifi
cation
envelop
protein
virus
secret
toxin
bacteria
parasit
sporul
dormanc
bacteria
virus
fungi
activ
effl
ux
pump
bacteria
fungi
parasit
decreas
permeabl
cell
wall
bacteria
fungi
virul
factor
imped
cellular
function
solid
blockad
requir
success
erad
pathogen
hostdirect
therapi
counter
mechan
target
impair
intracellular
process
aff
ect
host
cell
blue
arrow
mechan
activ
autophagi
apoptosi
induct
oxid
nitros
stress
increas
antigen
process
present
turn
trigger
necessari
adapt
immun
respons
novel
hostdirect
therapeut
strategi
target
host
surfac
receptor
program
deathligand
involv
immun
exhaust
sialic
acidcontain
receptor
sar
enhanc
entri
pathogen
host
cell
histon
modifi
cation
done
target
gene
involv
pathogen
replic
induct
apoptosi
autophagi
antigen
process
present
fattyacid
metabol
might
role
mainten
memori
cytotox
tlymphocyt
pool
host
respons
induc
hostdirect
therapi
might
counteract
microbi
virul
factor
dot
blockad
addit
neutralis
tissu
damag
suggest
hostdirect
eff
ect
analys
patient
com
munityacquir
pneumonia
bacteraemia
caus
communityacquir
pneumonia
sever
sepsi
show
benefi
specifi
c
macrolid
restrict
pneumococc
bacteraemia
also
shown
gramneg
bacteri
infect
find
suggest
macrolid
provid
benefi
mainli
patient
sever
ill
use
nonsteroid
antiinfl
ammatori
drug
nsaid
treatment
pneumonia
peopl
yield
confl
ict
result
studi
investig
review
eff
ect
ibuprofen
patient
sepsi
pneumonia
show
improv
ga
exchang
albeit
without
eff
ect
mortal
statin
reductas
inhibitor
might
role
adjunct
treatment
communityacquir
pneumonia
via
pleiotrop
antiinfl
ammatori
antioxid
immuno
modulatori
eff
ect
howev
eff
ect
need
defi
ned
randomis
control
trial
observ
studi
patient
statin
develop
pneumonia
infect
less
like
develop
sepsi
die
sepsi
complic
lead
intens
care
unit
admiss
studi
examin
addit
statin
adjunct
therapi
pneumonia
develop
oral
hypoglycaem
agent
glitazon
may
antiinfl
ammatori
eff
ect
similar
corticosteroid
patient
communityacquir
pneumonia
glyburid
associ
signifi
cantli
lower
mortal
patient
sever
melioidosi
patient
without
diabet
patient
take
diabet
agent
fi
nding
warrant
clinic
investig
establish
whether
oral
hypoglycaem
agent
potenti
hostdirect
therapi
sever
com
munityacquir
pneumonia
helicobact
pylori
emerg
major
human
pathogen
role
gastric
cancer
classifi
ed
type
carcinogen
gastric
ulcer
world
popul
infect
pathogen
coevolv
human
be
almost
year
rais
concentr
interleukin
gut
individu
h
pylori
infect
postul
risk
factor
infl
ammatori
tissu
transform
damag
carcinogenesi
eff
ort
develop
hostdirect
therapi
h
pylori
infect
focus
neutralis
proinfl
ammatori
cytokin
mono
clonal
antibodi
eg
antiinterleukin
gevokizumab
adalimumab
cours
antibiot
treatment
clear
infect
vitamin
also
potenti
use
hostdirect
therapi
h
pylori
infect
preclin
studi
gastric
epitheli
cell
line
infect
h
pylori
vitamin
supplement
augment
kill
intracellular
bacteria
via
induct
cathelicidin
bordetella
pertussi
remain
import
caus
morbid
mortal
antibiot
substanti
aff
ect
cours
whoop
cough
diseas
unless
treatment
start
earli
symptom
onset
mani
patient
develop
longterm
pulmonari
damag
immunotherapi
antipertussi
toxin
antibodi
might
confer
protect
sever
form
whoop
cough
halperin
colleagu
investig
use
multipl
dose
intraven
antipertussi
immunoglobulin
infant
pertussi
infect
note
increas
serum
antipertussi
antibodi
titr
declin
lymphocytosi
reduct
paroxysm
cough
compar
baselin
howev
fi
nding
recent
studi
antipertussi
immunoglobulin
promis
manipul
signal
pathway
involv
sever
immunolog
process
includ
lymphocyt
traffi
cking
might
therapeut
benefi
ts
revers
patholog
outcom
pertussi
diseas
appendix
number
infect
antibioticresist
neisseria
gonorrhoea
increas
worldwid
histon
deacetylas
inhibitor
sulforaphan
induc
express
antimicrobi
peptid
eg
secretori
leucocyt
proteas
inhibitor
shown
augment
activ
antibiot
multidrugresist
n
gonorrhoea
thu
show
potenti
hostdirect
therapi
supernat
human
endocerv
carcinoma
cell
pretreat
sulforaphan
potenti
better
bacteri
kill
combin
subleth
dose
ciprofl
oxacin
cefi
xime
compar
antibiot
alon
furthermor
sulforaphan
treatment
n
gonorrhoeaeinfect
femal
mice
result
better
control
bacteri
load
reduc
infl
ammat
treatment
cervic
cell
sulforaphan
combin
antibiot
therapi
might
reduc
amount
antibiot
need
erad
n
gonorrhoea
see
appendix
discuss
hostdirect
therapi
bacteri
sepsi
hiv
target
infect
human
cell
caus
aid
imped
tcellmedi
respons
wide
rang
microb
pharmacolog
activ
autophagi
apoptosi
drive
improv
intracellular
kill
pathogen
enhanc
antigen
present
activ
recruit
antigenpres
cell
ie
dendrit
cell
macrophag
via
therapi
proinfl
ammatori
cytokin
interferon
granulocytemacrophag
colonystimul
factor
gmcsf
protein
among
other
could
amplifi
antimicrobi
immun
respons
sever
anticanc
drug
ie
cisplatin
gemcitabin
paclitaxel
potenti
antigenspecifi
c
cytotox
tlymphocyt
ctl
respons
patient
induc
product
interleukin
il
tumour
necrosi
factor
il
immun
checkpoint
inhibit
block
program
cell
death
program
deathligand
pathway
activ
antigenspecifi
c
cell
invitro
select
expans
pathogenspecifi
c
autolog
tcell
subset
antigenspecifi
c
cell
ctl
allow
reinfus
patient
confi
rmation
activ
blockad
cell
surfacebound
signal
molecul
receptor
il
neuropilin
may
potenti
specifi
c
tcell
respons
remov
excess
infl
ammatori
cytokin
use
monoclon
antibodi
deplet
regulatori
cell
treg
cytotox
agent
eg
cyclophosphamid
etoposid
dampen
destruct
infl
ammat
target
organ
might
reorient
mycobacterium
tuberculosistarget
immun
respons
ctl
histon
deacetylas
inhibitor
valproic
acid
vorinostat
might
reprogramm
nonproduct
cell
antigenspecifi
c
cell
infus
autolog
mesenchym
stromal
cell
msc
could
neutralis
local
cytokin
milieu
promot
tissu
repair
orchestr
antigenspecifi
c
tcell
respons
multidrugresist
tuberculosi
hostcel
surfac
receptor
use
pathogen
entri
could
target
hostdirect
therapi
ampantimicrobi
peptid
bcrbcell
receptor
mcsfmacrophag
colonystimul
factor
tcrtcell
receptor
tgftransform
growth
factor
vegfvascular
endotheli
growth
factor
mechan
action
development
stage
repurpos
drug
imatinib
verapamil
metformin
ibuprofen
encourag
result
earlyphas
clinic
trial
histon
deacetylas
inhibitor
treatment
latent
hiv
infect
could
revolutionis
art
sinc
express
hivspecifi
c
cytotox
lymphocyt
barrier
eff
ectiv
antivir
immun
respons
patient
aid
time
blockad
deathligand
pathway
could
viabl
option
pursu
invitro
blockad
alreadi
shown
improv
antihiv
cytotox
tlymphocyt
respons
mark
increas
prolifer
product
cytokin
cytotox
molecul
faster
recoveri
immun
compet
lymphopen
host
seen
hivposit
patient
treatment
recombin
interleukin
epsteinbarr
viru
ebv
human
herpesviru
ubiquit
remain
larg
latent
natur
least
world
popul
infect
viru
ebv
tropism
b
cell
caus
wide
rang
clinic
syndrom
selflimit
infecti
mononucleosi
lymphoprolif
syndrom
bcell
lymphoma
chimer
antigen
receptor
design
bcell
surfac
antigen
current
approv
elimin
latent
viral
reservoir
patient
decreas
chanc
develop
bcell
lymphoma
approach
also
feasibl
patient
ebvassoci
bcell
lymphoma
altern
transfer
ebvspecifi
c
cytotox
lymphocyt
initi
isol
patient
cultur
expand
ex
vivo
clinic
test
much
success
also
tcell
respons
shown
mediat
control
ebvinfect
cell
interleukin
produc
cell
shown
involv
ebv
nuclear
antigen
independ
express
latent
membran
protein
ebvcarri
type
cell
cytomegaloviru
anoth
ubiquit
human
herpesviru
infect
lung
eye
cn
gastrointestin
tract
caus
seriou
diseas
adult
children
particular
patient
recent
undergon
haemopoiet
stemcel
transplant
hsct
increas
risk
develop
clinic
cytomegaloviru
diseas
associ
cytomegaloviru
statu
donor
recipi
hsct
immun
control
larg
attribut
antigenspecifi
c
cytotox
lymphocyt
although
cell
activ
notic
subdu
hsct
result
immunosuppress
therapi
hostdirect
therapi
transfer
autolog
allogen
antigenspecifi
c
cytotox
lymphocyt
investig
mainli
hsct
set
time
strategi
crucial
avoid
cytomegalovirusassoci
immun
reconstitut
infl
ammatori
syndrom
hepat
c
viru
hcv
caus
least
liver
diseas
worldwid
lead
caus
liver
cirrhosi
hepatocellular
carcinoma
acut
chronic
stage
hcv
infect
liver
promot
tcell
exhaust
hiv
infect
characteris
express
virusspecifi
c
cytotox
lymphocyt
anoth
immun
checkpoint
cytotox
lymphocyteassoci
antigen
also
express
exhaust
cell
reduc
immun
reactiv
antihcv
eff
ector
cell
virusinfect
cytokin
therapi
interferon
interleukin
earli
stage
monoclon
antibodi
late
stage
cytokin
neutralis
reduc
tissuedestruct
infl
ammat
yet
test
trypanosomiasi
recombin
protein
cytokin
therapi
apolipoprotein
cytokineinduc
protein
directli
engag
kill
trypanosom
preclin
cellular
therapi
msc
late
stage
neutralis
tissuedestruct
infl
ammat
enhanc
organ
repair
yet
test
trypanosomiasi
schistosomiasi
cytokin
therapi
interleukin
interferon
earli
stage
induct
proinfl
ammatori
immun
respons
intracellular
antimicrobi
activ
yet
test
schistosomiasi
review
tissu
patient
current
fi
rstline
treatment
hcv
infect
combin
regimen
directact
antivir
drug
mandatorili
includ
nucleotid
analogu
sofosbuvir
despit
high
effi
caci
high
fi
nancial
cost
directact
antivir
drug
barrier
provis
hcv
treatment
monoclon
antibodi
nivolumab
shown
induc
product
clinic
respons
patient
hcv
infect
mark
pronounc
viral
load
reduct
ipilimumab
review
mellitu
receiv
metformin
treatment
increas
blood
glucos
concentr
requir
insulin
therapi
therapi
use
treatment
melanoma
solid
cancer
includ
hcvinduc
hepato
cellular
carcinoma
combin
hcvinfect
hepatocyt
secret
newli
form
virus
bound
apolipoprotein
b
apob
thu
make
increas
apob
express
risk
factor
infect
progress
activ
hepat
potenti
target
hostdirect
therapi
highli
express
liver
import
role
fattyacid
metabol
notabl
increas
level
circul
serum
sampl
patient
hcv
infect
genotyp
qualifi
es
diseas
biomark
target
hostdirect
therapi
phase
clinic
trial
miravirsen
santari
pharma
municip
denmark
antisens
oligonucleotid
target
patient
chronic
hcv
infect
recent
complet
previou
preclin
assess
show
promis
antivir
eff
ect
infl
uenza
viru
caus
sever
pandem
million
death
worldwid
mani
patient
infl
uenza
succumb
extens
lung
patholog
secondari
bacteri
pneumonia
resist
current
neuraminidas
inhibitor
present
major
hurdl
manag
futur
pandem
immunosuppress
treatment
etoposid
dampen
cytokin
storminduc
lung
patholog
clinic
benefi
cial
patient
sever
infl
uenza
infect
fl
udas
ansun
biopharma
san
diego
ca
usa
sialidas
fusion
peptid
cleav
sialic
acid
residu
host
epitheli
cellsurfac
receptor
follow
approv
us
food
drug
administr
fda
use
two
hsct
recipi
parainfl
uenza
infect
fi
rst
patient
die
wherea
second
recov
clinic
benefi
reduct
viral
load
report
phase
clinic
trial
patient
pneumonia
caus
either
infl
uenza
b
pandem
strain
sever
immuno
modulatori
drug
statin
angiotensiniireceptor
blocker
angiotensinconvert
enzym
inhibitor
peroxisom
proliferatoractiv
receptor
agonist
glitazon
fi
brate
respect
adenosin
monophosphateactiv
kinas
agonist
eg
metformin
suggest
modifi
host
respons
sever
infl
uenza
improv
surviv
sinc
intervent
shown
reduc
mortal
mice
infect
infl
uenza
viru
observ
studi
patient
admit
hospit
laboratoryconfi
rmed
infl
uenza
statin
reduc
number
death
hospit
within
day
discharg
observ
studi
show
inpati
treatment
angiotensiniireceptor
blocker
angiotensinconvert
enzym
inhibitor
statin
reduc
pneumonia
mortal
respect
epidem
ebola
viru
diseas
diseas
caus
case
death
three
west
african
countri
clinic
trial
experiment
antivir
agent
antibodi
prepar
vaccin
complet
clinic
success
treat
patient
ebola
viru
infect
convalesc
plasma
individu
surviv
diseas
outbreak
democrat
republ
congo
prompt
use
strategi
ebola
outbreak
west
africa
although
intervent
provid
surviv
benefi
acut
kidney
lung
injuri
report
howev
advers
eff
ect
could
directli
attribut
convalesc
plasma
transfus
new
treatment
strategi
target
host
factor
ebola
viru
diseas
develop
recombin
nematod
anticoagul
protein
anticoagul
fda
approv
treatment
thrombosi
shown
promis
preclin
data
ebola
virusinfect
monkey
although
clinic
trial
current
list
endotheli
dysfunct
caus
fl
uid
electrolyt
imbal
seen
patient
ebola
viru
infect
invitro
studi
shown
statin
angiotensiniireceptor
blocker
preserv
restor
endotheli
barrier
integr
drug
could
consid
treat
host
respons
patient
sierra
leon
patient
ebola
viru
infect
treat
combin
report
suggest
substanti
extens
surviv
dengu
viru
belong
genu
fl
avivirus
also
includ
yellow
fever
viru
west
nile
viru
tickborn
enceph
viru
zika
viru
arthropodtransmit
infect
four
diff
erent
serotyp
dengu
viru
exist
infect
one
serotyp
protect
dengu
viru
infect
lead
establish
sever
haemorrhag
diseas
case
lead
shock
syndrom
fatal
hostdirect
therapi
lovastatin
known
modul
cholesterol
metabol
shown
inhibit
replic
dengu
viru
human
epitheli
cell
repurpos
drug
also
clinic
test
ivermectin
dasatinib
ciclosporin
addit
use
type
interferon
interferon
shown
promis
result
anim
model
nonhuman
primat
could
also
use
manag
vasculopathi
dengu
haemorrhag
fever
shock
syndrom
approach
requir
clinic
investig
middl
east
respiratori
syndrom
coronaviru
merscov
fi
rst
isol
june
jeddah
saudi
arabia
patient
die
sever
respiratori
infect
multiorgan
failur
merscov
associ
high
mortal
patent
comorbid
eff
ectiv
antimerscov
antivir
agent
therapeut
lung
patholog
seen
review
patient
mer
probabl
repres
end
result
fi
ne
balanc
host
immun
merscov
interact
invitro
laboratori
investig
identifi
ed
membranebound
form
dipeptidyl
peptidas
cardin
hostcel
receptor
viru
entri
pneumonia
common
featur
patient
mer
high
mortal
caus
merscov
attribut
acut
lung
injuri
develop
acut
respiratori
distress
syndrom
ard
ard
associ
leaki
alveolarcapillari
interfac
pulmonari
oedema
hypoxia
poli
morphonuclear
leucocyt
lymphocyt
cellular
infi
ltrate
aberr
immun
respons
upregul
proinfl
ammatori
cytokin
includ
interferon
result
tissu
damag
deterior
lung
function
analysi
serum
bronchoalveolar
lavag
fl
uid
sampl
patient
die
merscov
infect
show
nonproduct
infl
ammatori
immun
respons
induct
interleukin
interleukin
patient
acut
lung
injuri
ard
die
diseas
blockad
proinfl
ammatori
cytokin
interleukin
interleukin
sever
diseas
might
use
adjunct
therapi
need
assess
clinic
trial
addit
reinfus
bone
marrow
mesenchym
stem
cell
might
also
help
amelior
lung
patholog
critic
ill
patient
potenti
hostdirect
therapi
improv
treatment
outcom
mer
shown
tabl
plasmodium
falciparum
malaria
kill
million
peopl
worldwid
everi
year
individu
p
falciparum
infect
often
develop
sever
clinic
symptom
brain
damag
multipl
organ
failur
case
sever
clinic
malaria
fatal
even
access
best
health
care
partli
parasit
trigger
infl
ammat
damag
vital
organ
case
fatal
rate
sever
malaria
remain
high
even
best
clinic
set
antimalari
drug
act
parasit
without
allevi
lifethreaten
infl
ammat
drug
resist
threaten
effi
caci
artemisininbas
therapi
ferrochelatas
enzym
import
haem
biosynthesi
human
erythrocyt
report
instrument
parasit
surviv
human
erythrocyt
defi
cient
ferrochelatas
patient
erythropoiet
protoporphyria
resist
p
falciparum
growth
pharmacolog
inhibit
host
ferrochelatas
vitro
abrog
parasit
replic
healthi
human
erythrocyt
desferrioxamin
potent
inhibitor
ferrochetalas
could
consid
repurpos
human
malaria
excess
product
involv
pathogenesi
sever
malaria
clinic
studi
includ
gambian
children
malariaassoci
coma
treatment
antibodi
reduc
parasit
load
dosedepend
manner
noteworthi
anti
pyrogen
eff
ect
use
drug
eg
adalimumab
etanercept
sever
malaria
need
investig
clincial
trial
small
synthet
peptid
known
innat
defenc
regul
idr
seem
broad
therapeut
potenti
includ
invivo
activ
murin
model
enhanc
wound
heal
protect
staphylococcu
aureu
multidrugresist
tuberculosi
herp
simplex
viru
infl
ammatori
disord
includ
cerebr
malaria
recent
studi
plasmodium
berghei
anka
model
experiment
cerebr
malaria
show
idr
peptid
prevent
cn
infl
ammat
protect
mice
experiment
cerebr
malaria
improv
surviv
idr
peptid
enhanc
benefi
cial
aspect
initi
immun
respons
dampen
harm
tissu
damag
downregul
secret
proinfl
ammatori
cytokin
includ
interleukin
coadministr
standard
fi
rstline
antimalari
drug
pyrimethamin
chloroquin
increas
surviv
infect
mice
thu
idr
peptid
could
serv
adjunct
hostdirect
therapi
sever
diseas
combin
antimalari
treatment
leishmania
spp
caus
rang
clinic
diseas
includ
cutan
mucocutan
viscer
involv
like
intracellular
pathogen
leishmania
spp
parasit
diffi
cult
kill
localis
protect
immun
respons
chemotherapi
drug
treatment
limit
effi
caci
use
lengthi
period
time
system
sideeff
ect
sometim
outweigh
clinic
benefi
ts
thu
success
treatment
diseas
caus
intracellular
pathogen
might
need
combin
therapi
eff
ectiv
deliveri
system
imiquimod
resiquimod
current
use
treatment
leishmaniasi
trigger
tolllik
receptor
tlr
innat
immun
respons
induc
product
interleukin
type
interferon
thu
act
hostdirect
manner
overproduct
leishmania
braziliensi
infect
contribut
mucos
tissu
damag
consequ
lead
develop
mucocutan
leishmaniasi
case
com
binat
antileishmani
drug
adalimumab
activ
l
braziliensi
infect
might
yield
clinic
respons
preclin
studi
deliveri
nanocapsul
doxorubicin
formul
includ
chondroitin
sulfat
hamster
increas
kill
leishmani
promastigot
via
augment
immun
respons
via
induct
interferon
interleukin
releas
addit
direct
antiparasit
activ
sequenti
chemoimmunotherapi
singl
low
dose
liposom
amphotericin
b
novel
tcellepitopeenrich
dna
vaccin
candid
leishdnavax
mologen
ag
germani
test
hostdirect
therapi
vaccin
candid
boost
effi
caci
singl
suboptim
dose
liposom
amphotericin
b
mice
polyhexanid
cation
polym
abl
directli
wwwthelancetcominfect
vol
april
review
kill
leishmania
major
enhanc
hostdirect
kill
improv
deliveri
immunomodulatori
nucleic
acid
polyhexanid
spontan
bind
cpg
odn
short
synthet
oligodeoxynucleotid
compris
cytosin
triphosph
c
guanin
triphosph
g
residu
sequenti
order
form
stabl
nano
polyplex
enhanc
uptak
cpg
odn
potenti
antimicrobi
kill
reduc
hostcel
toxic
polyhexanid
fi
nding
warrant
investig
trypanosoma
spp
caus
human
trypanosomiasi
two
import
vectorborn
diseas
human
african
trypanosomiasi
also
known
sleep
sick
caus
trypanosoma
brucei
gambiens
brucei
rhodesiens
chaga
diseas
caus
trypanosoma
cruzi
sever
patholog
patient
human
african
trypanosomiasi
lead
fatal
meningoencephalopathi
mani
case
coma
chaga
diseas
patient
prone
infecti
myocard
meningoenceph
often
lifethreaten
progress
damag
autonom
nervou
system
occur
organ
enlarg
ment
failur
mous
model
brucei
infect
equilibrium
earli
onset
respons
interferon
late
respons
interleukin
interleukin
control
parasitaemia
associ
patholog
addit
nitric
oxid
mhci
antigen
process
present
cytotox
tlymphocyt
activ
role
elimin
parasit
reservoir
macrophag
human
be
cytokin
analysi
cerebrospin
fl
uid
specimen
show
patient
latestag
human
african
trypanosomiasi
rais
level
proinfl
ammatori
cytokin
includ
interleukin
interleukin
monocyt
chemotact
protein
also
known
macrophag
infl
ammatori
protein
mip
among
other
destruct
infl
ammat
might
amen
cellular
therapi
latestag
human
african
trypanosomiasi
wherea
immunostimulatori
treatment
vitamin
interferon
interleukin
could
use
earli
stage
apolipo
protein
known
host
factor
antitrypanosom
activ
thu
activ
immun
system
earli
stage
interferon
could
help
control
burden
parasitaemia
via
diff
erent
eff
ector
mechan
sinc
immun
respons
profi
le
chaga
diseas
similar
human
african
trypanosomiasi
hostdirect
therapi
relev
human
african
trypanosomiasi
might
also
benefi
patient
cruzi
infect
addit
antiparasit
therapi
schistosomiasi
aff
ect
million
peopl
countri
caus
trematod
parasit
genu
schistosoma
major
clinic
manifest
aris
patholog
due
granulomat
reaction
around
ova
major
organ
bodi
especi
urinari
gastrointestin
tract
antischistosom
immun
respons
milieu
mainli
consist
cytokin
interferon
interleukin
interleukin
interleukin
interleukin
also
seem
import
role
earli
infect
schistosoma
spp
cercaria
cient
mice
repeatedli
infect
schistosoma
mansoni
tcell
activ
pronounc
target
effi
cient
upon
exposur
schistosoma
antigen
prepar
fi
nding
extrapol
human
be
would
suggest
multipl
exposur
mansoni
might
reduc
tcell
respons
manner
henc
weaken
product
cellular
immun
respons
use
interleukin
interferon
might
help
recov
tcell
respons
patient
endem
countri
notabl
use
cytokin
interleukin
interleukin
mixtur
schistosom
dehydrogenas
peroxiredoxin
postexposur
vaccin
attempt
result
immens
reduct
migrat
cercaria
mansoniinfect
mice
hostdirect
therapi
target
host
immun
infl
ammatori
pathway
enhanc
immun
respons
allevi
immunopatholog
could
benefi
treatment
outcom
rang
bacteri
viral
parasit
diseas
variabl
potenti
adjunct
hostdirect
therapi
deliv
clinic
meaning
benefi
pathogen
demand
defi
nition
defi
nition
part
depend
eff
ectiv
standard
antimicrobi
therapi
whether
tissu
damag
event
repres
therapeut
target
otherwis
address
convent
treatment
focu
hostdirect
therapeut
strategi
across
variou
infecti
diseas
requir
invest
multidisciplinari
research
col
labor
academ
industri
partner
develop
take
forward
assess
hostdirect
therapi
search
pubm
cochran
librari
embas
googl
scholar
articl
publish
english
nov
jan
term
infecti
diseas
parasit
diseas
combin
term
host
hostdirect
therapi
hostdirect
treatment
adjunct
therapi
adjunct
treatment
immunotherapi
cellular
therapi
repurpos
drug
therapeut
advanc
treatment
treatment
regimen
trial
clinic
trial
anim
model
also
found
public
search
websit
manufactur
antiinfect
drug
immunebas
therapi
also
review
studi
publish
nov
jan
cite
articl
identifi
ed
search
strategi
select
identifi
ed
relev
select
review
articl
cite
provid
reader
detail
nd
refer
review
accommod
